A Case of Capri-Ruzumab-induced Telangiectasia in the Treatment of Liver Cancer and the Research Progress of Traditional Chinese and Western Medicine

Authors

  • Liangliang Li Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Yanli Zhao Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, Shaanxi, China
  • Yupei Wang Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Yaoqi Wen Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China

DOI:

https://doi.org/10.53469/jcmp.2025.07(10).12

Keywords:

Liver cancer, Camrelizumab, Capillary proliferation, Cutaneous toxicity, Immunotherapy

Abstract

Reactive capillary hyperplasia is a cutaneous toxicity-related adverse reaction caused by immunotherapy with PD-L1 immune checkpoint inhibitors in cancer patients. Compared to other immune checkpoint inhibitors, Carililuzumab has a higher incidence rate. This article aims to share the medical records of a liver cancer patient who developed reactive capillary hyperplasia caused by Carililuzumab. Additionally, it conducts a literature analysis on the research progress of treating capillary hyperplasia with traditional Chinese and Western medicine, to enhance clinicians’ understanding of the adverse reactions associated with this drug and expand treatment options for these adverse reactions.

Downloads

Published

2025-10-30

How to Cite

Li, L., Zhao, Y., Wang, Y., & Wen, Y. (2025). A Case of Capri-Ruzumab-induced Telangiectasia in the Treatment of Liver Cancer and the Research Progress of Traditional Chinese and Western Medicine. Journal of Contemporary Medical Practice, 7(10), 60–65. https://doi.org/10.53469/jcmp.2025.07(10).12

Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /www/bryanhousepub/ojs/plugins/generic/citations/CitationsPlugin.inc.php on line 49